Emerging HIV Drug Resistance in the Resource-Poor World: Challenges and Strategies

At the end of 2011, more than 8 million People Living with HIV (PLWH) were receiving Anti-retroviral Therapy (ART) in lowand middle-income countries [1]. Accordingly, the advent and extensive use of Highly Active Anti-retroviral Therapy (HAART) has dramatically reduced the mortality and morbidity associated with the HIV infection worldwide [2]. However, many factors such as missing doses of medications, interruptions in ART and mono-therapy in the pre-HAART era may ultimately result in clinical drug resistance and virologic failure [3-8].